title: [Progress of research and development of MAPK pathway inhibitors].
authors.affiliation: ishiinby@chugai-pharm.co.jp
authors.forename: Nobuya
authors.initials: N
authors.lastname: Ishii
mesh_terms: D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001562:Benzimidazoles / Q000008:administration & dosage / Q000494:pharmacology; D055808:Drug Discovery / Q000639:trends; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage / Q000494:pharmacology; D007211:Indoles / Q000008:administration & dosage / Q000494:pharmacology; D020935:MAP Kinase Signaling System / Q000187:drug effects* / Q000502:physiology; D020928:Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000188:drug therapy*; D010091:Oximes / Q000008:administration & dosage / Q000494:pharmacology; D011728:Pyridones / Q000008:administration & dosage / Q000494:pharmacology; D011744:Pyrimidinones / Q000008:administration & dosage / Q000494:pharmacology; D012106:Research / Q000639:trends; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D000077484:Vemurafenib; D048490:raf Kinases / Q000037:antagonists & inhibitors* / Q000502:physiology
chemical_list: C517975:AZD 6244; D001562:Benzimidazoles; D007093:Imidazoles; D007211:Indoles; D010091:Oximes; D011728:Pyridones; D011744:Pyrimidinones; D013449:Sulfonamides; D000077484:Vemurafenib; C560077:trametinib; D048490:raf Kinases; D020928:Mitogen-Activated Protein Kinases; C561627:dabrafenib